Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol PRDM2 contributors: mct - updated : 31-03-2008
HGNC name PR domain containing 2, with ZNF domain
HGNC id 9347
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a PR/SET motif at its N-terminus (AA 30
    • 140)
  • eight zinc finger motifs
  • Krüppel-like with the PRD domain (PRD1-BF1-RIZ1), lacking in RIZ2, leucine zipper, GTPase, SH3 and pRB domains
  • a PR binding domain in the C terminal region, flexible, similar to SET domains, mediating interactions or oligomerization, and involved in methylation of H3
  • a SET domain
    • HOMOLOGY
    interspecies homolog to murine Prdm2
    Homologene
    FAMILY
  • nuclear histone/ protein methyltransferase superfamily
  • PR-domain protein family
    • CATEGORY enzyme , transcription factor
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus
    basic FUNCTION
  • histone methyltransferase, acting as a putative tumor suppressor
  • transcriptional regulation during neuronal differentiation
  • involved in B cell differentiation and the development of B cell lymphomas
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule metal binding,
  • Zn2+
    • protein
  • RIZ interacting
  • associate with promoter regions of IGF1 and increase histone H3 lysine 9 methylation (may contribute to potential CML tumor suppressor properties of PRDM2
  • interacting with YY1 (coexpression of PRDM2/YY1 proteins suggests a tandem regulatory mechanism in human osteosarcoma cells and tissues)
    • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in acute lymphoblastic leukemia
    tumoral       loss of function
    by DNA methylation in liver and breast and stomach cancer
    tumoral   LOH    
    in pheochromocytomas and paragangliomas
    tumoral       loss of function
    in pheochromocytomas and paragangliomas
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancerhemopathy 
    therapeutic potential of inhibiting IGF1 pathway in the acute phase of CML (chronic myelogenous leukemia)
    ANIMAL & CELL MODELS